Training Session for Physiotherapists and Occupational Therapists on Outcome Measures in Spinal muscular atrophy hosted by Quebec SMA Network

This past March, the Quebec SMA Network (Réseau québécois de l’amyotrophie spinale – RQAS) in collaboration with the NMD4C and Muscular Dystrophy Canada (MDC) hosted an interactive training session for French-speaking physiotherapists (PT) and occupational therapists (OT) on assessment measures and practices for Spinal muscular atrophy (SMA). This training gathered PTs and OTs to train and discuss SMA standardized outcome measures and work through current problems/challenges, to improve how these measures often tied to drug reimbursement are conducted. 

Thank you to everyone who attended! Special thanks to Dr. Xavier Rodrigue, Sarah Turgeon Desilets, Mélanie Claveau, Monique Emond, Catherine Desautels, Isabelle Demers, Amy Loignon, and Catherine Boivin. The event report is being developed, and additional virtual and in-person English training session will be organized before the end of the year. This event would not have been possible without restricted support from Roche and Biogen.  

Please contact us at and if you have any questions about SMA outcome measures or if you are a healthcare professional interested in events like this.

Event organizers and participants from SMA outcome measures training, March 2024 in Quebec.

Read next...

Hope On The Horizon: Trials Treatments and Therapies for DMD, DM1 and MG

Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG

Nov 26-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!

Website - 2026 Awards Now Open

2026 Awards Now Open for Nominations!

We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.